BrainsWay Ltd. is a medical device company specializing in noninvasive neurostimulation treatments for mental health disorders. The company develops and markets the Deep Transcranial Magnetic Stimulation (Deep TMS) platform, which uses proprietary H-Coils to stimulate deep and broad brain regions. Its primary indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, with FDA clearance for the first two and marketing for the third in the United States. BrainsWay also holds CE Mark approval for various psychiatric and neurological indications in other markets. The company serves patients through a network of healthcare providers and has entered into investment transactions with multi-specialty groups (MSOs) to expand access to its treatments. Founded in 2003, BrainsWay conducts research and development in Israel and the United States, focusing on advancing its clinical pipeline for additional psychiatric, neurological, and addiction disorders.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Medical Devices Homepage brainsway.com
Sector Healthcare IR page brainsway.com
Tags
neurostimulation, transcranial magnetic stimulation, major depressive disorder, obsessive-compulsive disorder, smoking cessation, mental health, noninvasive brain stimulation, h-coils, Deep TMS
Press page brainsway.com/newscat/news

Metrics

Valuation  
Market cap $ 529.708M
Market cap (USD) $ 529.708M
P/E 82.50
PEG —
P/BV 6.69
P/S 8.73
P/OCF 69.97
P/FCF 32.55
Dividend yield —
Turnover / mcap —
Returns  
ROE 11.2%
ROI 67.6%
ROIC 37.9%
Profit margin 14.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 108
Quality score 18.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 52.225M 41.016M 31.785M 27.177M 29.657M 22.057M 23.101M 16.397M
Net profit 7.575M 2.921M -4.197M -13.349M -6.462M -5.385M -10.328M -6.479M
Free cash flow 16.273M 6.504M -1.103M -9.76M -1.354M -3.906M -10.555M -5.745M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 19.02 9.43 6.48 2.47 7.7 7.54 9.75 —
Price performance 12m 1.02 0.46 1.62 -0.68 0.02 -0.23 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (USD) 5.34M 6.16M 7.88M 5.82M 6.39M 7.68M 6.67M 7.19M 9.6M
↳ 5y CAGR +7.5% +1.6% -1.8% +10.5%
Reported Mar 23, 2020 Mar 23, 2020 Mar 23, 2020 Apr 19, 2021 Apr 12, 2022 Mar 27, 2023 Mar 28, 2024 Apr 22, 2025 Apr 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Revenue increased 34% to $18.1 million in Q3 2026; Operating income rose 107% to $2.6 million and Adjusted EBITDA rose approximately 92% to $3.9 million

Remaining performance obligations grew 31% year-over-year to approximately $85 million

Shipped 130 Deep TMS systems in Q3 2026, a 44% increase year-over-year

Full-year 2026 revenue, operating income margin and Adjusted EBITDA expected at the upper end of guidance with potential to modestly exceed it

BURLINGTON, Mass. and JERUSALEM, Nov. 10, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today reported its third quarter 2026 financial results and provided an operational update.

“Our third-quarter results demonstrate our ability to translate strong revenue growth into higher profitability and cash generation. Revenue increased 34%, while operating income grew 107% and operating cash flow reached $6.2 million,” said Hadar Levy, Chief Executive Officer of BrainsWay.

D I S C L A I M E R Investor Deck | November 2026 2 Safe Harbor and Non - GAAP/IFRS Financial Measures T h i s p r es e n t a t i o n do e s n o t c on s t i tut e a n o ff e r o r i n v i t a t i o n t o se l l o r iss u e , o r a n y s o li c i t a t i o n o f a n o ff e r t o s ub s c ri b e f o r o r a c q u ir e , a n y s e c u r i t ie s o f th e C o m p a n y , n o r t o p ar t i c i p a t e i n a n y i n v e s t me n t . T h i s pr e s e n t a t i o n s h a l l n o t c o n s t i tu t e a d v er t i s i n g o r b e c o n s t rue d a s c omm er c i a l o r p r omo t i o n a l i n n a tu r e . N o repr e s e n t a t i o n o r w a r r a n t y i s m a d e a s t o t h e a cc u r a c y o r c om p l e te n e s s o f th i s p r es e n t a t i o n . Y o u m u s t m a k e y o u r o w n i n v e s t i ga t i o n a n d assessme n t o f t h e m a t t e r s c o n t ai n e d h er e i n . I n p a r t i c u l a r , n o r e s p o n s i b il i t y i s ass u m e d a s t o th e a c h ie v em e n t o r re as o n a b l e n es s o f a n y f o r e c a s t s , e s t im a t es , o r s t a t eme nt s a s t o p r o s p e c t s c o nt ai n e d o r re f er r e d t o i n th i s p r ese n t a t i o n .

Latest Collaboration Comes Amid Progress in Other Strategic Initiatives, Including Follow-on Investment in Earlier Minority Stake Investment Target

BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced a strategic collaboration with Mindful Health Solutions (“MHS”), an established provider of comprehensive behavioral health and interventional psychiatry services. In August, Mindful Health Solutions’ managed services organization was acquired by Radial Health, Inc. The combined management company, operating under the Radial banner, now supports the largest network of brain medicine clinics in the US, operating 27 locations across California, Missouri, New York, South Carolina, Tennessee, Texas and Washington.

Prompts

BrainsWay Ltd. (ticker BWAY), listed in United States.

ETFs Holding BrainsWay Ltd.

ETF Weight in ETF Shares Market value As of
APIE 0.02% 17,211 $ 249.904K Aug 31, 2026